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Abstract
The herpesviruses, like most other DNA viruses, replicate in the host cell nucleus. Subnuclear domains known as
promyelocytic leukemia protein nuclear bodies (PML-NBs), or ND10 bodies, have been implicated in restricting early
herpesviral gene expression. These viruses have evolved countermeasures to disperse PML-NBs, as shown in cells infected in
vitro, but information about the fate of PML-NBs and their functions in herpesvirus infected cells in vivo is limited. Varicella-
zoster virus (VZV) is an alphaherpesvirus with tropism for skin, lymphocytes and sensory ganglia, where it establishes
latency. Here, we identify large PML-NBs that sequester newly assembled nucleocapsids (NC) in neurons and satellite cells of
human dorsal root ganglia (DRG) and skin cells infected with VZV in vivo. Quantitative immuno-electron microscopy
revealed that these distinctive nuclear bodies consisted of PML fibers forming spherical cages that enclosed mature and
immature VZV NCs. Of six PML isoforms, only PML IV promoted the sequestration of NCs. PML IV significantly inhibited viral
infection and interacted with the ORF23 capsid surface protein, which was identified as a target for PML-mediated NC
sequestration. The unique PML IV C-terminal domain was required for both capsid entrapment and antiviral activity. Similar
large PML-NBs, termed clastosomes, sequester aberrant polyglutamine (polyQ) proteins, such as Huntingtin (Htt), in several
neurodegenerative disorders. We found that PML IV cages co-sequester HttQ72 and ORF23 protein in VZV infected cells. Our
data show that PML cages contribute to the intrinsic antiviral defense by sensing and entrapping VZV nucleocapsids,
thereby preventing their nuclear egress and inhibiting formation of infectious virus particles. The efficient sequestration of
virion capsids in PML cages appears to be the outcome of a basic cytoprotective function of this distinctive category of PML-
NBs in sensing and safely containing nuclear aggregates of aberrant proteins.
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Introduction
Promyelocytic leukemia protein (PML) is a major organizing
component of structures that are referred to as PML nuclear bodies
(PML-NBs) or nuclear domain 10 (ND10) bodies [1–3]. These
nuclear bodies are heterogenous in size, shape and molecular
composition [4–6], are prominent in most mammalian cell types
and participate in many basic cellular functions, including
transcriptional regulation [7], DNA repair [8] and apoptosis [9–
12]. Human PML, located on chromosome 15, has nine exons and
alternative splicing of PML transcripts produces at least 11 isoforms
[13,14].PMLisoformssharea conservedN-terminus,whichhasthe
characteristic RBCC/TRIM motif, including a RING finger
domain, B boxes and a coiled coil domain. The PML N-terminus
is important for PML heterodimer formation and oligomeriztion
but each isoform has a unique C-terminal domain [14,15]. The
PML isoforms create PML-NBs with varying morphologies but the
functional implications of these differences are not well understood
[16–18]. While little is known about the tissue or cell specific
patterns of expression of individual PML isoforms, these non-
conserved PML regions are of interest for their likely involvement in
isoform-dependent functions within particular cell types and in the
response to changing intracellular or extracellular conditions [17].
Since their discovery, PML protein and PML-NBs have been
investigated for their role in the virus-host cell interactions of DNA
viruses that must replicate in the mammalian cell nucleus [19,20].
These viruses include the very extensive Herpesviridae family as
well as adenoviruses, papillomaviruses, polyomaviruses and other
pathogens. During herpesvirus infection, genome copies are
synthesized in nuclear replication compartments and genomic
DNA is packaged into icosahedral nucleocapsids (NCs) formed by
the major capsid protein and smaller capsid surface proteins. After
assembly, NCs egress across the nuclear membrane for secondary
envelopment in the cytoplasm and release as infectious virus
particles [21,22]. PML-NBs have been implicated in controlling
the replication of herpes simplex virus (HSV) 1 and human
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early viral gene transcription [19,20,23,24]. To overcome these
antiviral effects, HSV-1 targets PML for immediate proteosome-
mediated degradation through functions of the viral ICP0
ubiquitin ligase protein [25–28]. PML is also an interferon
(IFN)-inducible protein and must be degraded to prevent IFN-
mediated inhibition of HSV-1 [29]. Like HSV-1, varicella-zoster
virus (VZV) is a common human alphaherpesvirus [30]. In
contrast to HSV-1 infection, PML protein and some PML-NBs
persist in VZV-infected cells [31] although not in association with
early nuclear replication compartments [32]. Depleting PML
enhances VZV replication, suggesting a possible role for PML in
the host cell defense [31].
VZV, which causes varicella (chickenpox) and herpes zoster
(shingles), is a highly human-restricted pathogen [30,33]. Howev-
er, VZV pathogenesis can be investigated in vivo using xenografts
of human dorsal root ganglia (DRG) and skin in a severe
combined immunodeficiency (SCID) mouse model [34–36]. This
model allows the analysis of viral and cellular mechanisms that
facilitate or inhibit VZV when differentiated neural and skin cells
are infected within their usual tissue microenvironments in vivo and
in the absence of antiviral effects mediated by the adaptive
immune response [37,38]. The fundamental importance of
intrinsic and innate cellular responses in achieving the usual
balance between VZV and its human host is evident from the
observations that VZV undergoes a transition to persistence in
neurons within DRG xenografts without requiring VZV-specific
adaptive immunity [36] and that VZV skin infection is highly
regulated by type-I interferon produced by epidermal cells [39]. In
these experiments, we have used the SCID mouse model to define
VZV interactions with PML-NBs in human neural and epidermal
cells infected with this nuclear replicating DNA virus in vivo.
The characteristics and functions of PML-NBs in human neural
cells are of particular interest because VZV is a neurotropic
herpesvirus [30]. Aberrant proteins generated in several neurode-
generative diseases, including Huntington’s disease and spinocere-
bellar ataxias, accumulate in PML-NBs within neural cells and the
usual nuclear distribution of PML is altered by their expression [40–
45]. These diseases, classified as polyglutamine (polyQ) disorders,
are associated with an unstable CAG repeat expansion resulting in
the elongation of a polyglutamine (polyQ) tract in the abnormal
gene product [46]. The mis-folded, oligomeric polyQ proteins are
neurotoxic and form intranuclear aggregates, often with PML and
proteins of the ubiquitin-proteasome system [47,48]. Similar
structures have been referred to as clastosomes [44,49] and in
some cases appear to protect the cell by confining the abnormal
proteins to an intranuclear ‘‘safehouse’’ where they may be
degraded [44,50–52]. Here we report that endogenous PML forms
distinctive, large PML-NBs consisting of spherical cages in the
nuclei of neurons and satellite cells in human DRG and in skin cells
during VZV pathogenesis. These nuclear organelles efficiently
entrap newly assembled VZV capsids in vivo as well as in cultured
cells in vitro. The PML-NBs closely resemble those that retain polyQ
proteins in neurodegenerative diseases. Exogenous PML IV was the
only isoform that sequestered VZV NCs and interacted with the
ORF23 capsid surface protein, functions that required its unique C-
terminus. PML IV-NBs also retained the Huntington’s disease
protein, Htt, and could simultaneously sequester NCs. Importantly,
the nuclear entrapment of viral capsids in PML IV-NBs inhibited
the production of infectious VZV progeny. These observations
suggest that PML-NBs can retain nascent virion capsids in the
infected cell nucleus, resulting in an intrinsic antiviral defense at
later stages of viral replication.
Results
PML-NBs Colocalize with the ORF23 Capsid Protein in
VZV-infected Cells
Since PML protein and some PML-NBs persist in VZV infected
cells [31], we first investigated the intracellular localization of VZV
proteins that are found in nuclear viral replication compartments,
including ORF29, the single stranded DNA binding protein and
IE62, the major viral transactivating factor, as well as the ORF23
capsid protein, which is present in later stages of VZV infection
when progeny virion assembly occurs [32]. As expected, analysis
of uninfected human embryonic lung fibroblasts (HELF) by
confocal microscopy showed numerous PML-NBs that contained
both PML and SP100 protein, which are known components of
PML-NBs [53](Figure 1A). In infected HELF, PML-NBs did not
colocalize with viral DNA replication compartments, which were
identified by ORF29 and IE62 expression [32], at this late time at
24 hr after infection (Figure S1A and B).
In marked contrast, the newly synthesized ORF23 capsid
protein was present in almost all PML-NBs (94%, N=228) at this
stage of VZV infection (Figure 1B, left panel) using confocal
imaging conditions that were optimized to identify bright PML-
NBs associated with NCs. Based on its homology to the HSV-1
VP26 small capsid protein, ORF23 protein is predicted to be
exposed on VZV NCs [54]. ORF23 protein was similarly enriched
in PML-NBs in HELF infected with a VZV recombinant virus
that expresses ORF23 protein tagged with the red fluorescent
protein (RFP-ORF23) (Figure 1B, right panels) as well as in
melanoma cells (Figure S2A). The number of PML-NBs decreased
by about five-fold in both HELF and melanoma cells at 48 hr after
infection compared to uninfected HELF and melanoma cells
(Figure 1C and Figure S2B). Since melanoma cells have fewer
PML-NBs than HELF before infection, the majority of infected
melanoma cells had no PML-NBs left (Figure S2C). However, as
previously reported [31], immunoblot analysis with a polyclonal
anti-PML antibody showed that PML protein levels were not
decreased in infected HELF or melanoma cells (Figures 1D and
Author Summary
Many DNA viruses, including varicella-zoster virus (VZV), a
herpesvirus that causes varicella (chickenpox) and zoster
(shingles), replicate in the host cell nucleus. Here, we have
identified an intrinsic antiviral mechanism that specifically
targets newly assembled VZV capsids and contains these
essential viral structures in a nuclear ‘‘safe house’’. Using
immuno-electron microscopy, PML (promyelocytic leuke-
mia) protein fibers that formed filamentous spherical cages
were shown to trap virion capsids very efficiently,
preventing their transport out of the nucleus and
inhibiting the formation of infectious virus particles. PML
cages containing virion capsids were found in VZV-
infected neurons and satellite cells in human sensory
ganglia and in skin cells, which are major targets during
VZV pathogenesis. Similar PML nuclear bodies that
sequester abnormal proteins have been reported in
neurodegenerative disorders, like Huntington’s disease.
We found that cages formed by PML isoform IV
sequestered both the virion capsids of VZV, which is a
neurotropic herpesvirus, and the mutant Huntington’s
disease protein. This work provides the first evidence that
PML, which is abundant in mammalian cell nuclei, can
function both to contain potentially damaging cellular
protein aggregates and as an intrinsic host defense against
a herpesvirus during nuclear virion assembly.
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may represent different PML isoforms or post-translational
modifications of one or more of the PML isoforms. PML-NBs
that colocalized with ORF23 protein in infected cells were also
significantly larger than those in uninfected cells (Figure 1E).
These results suggested that PML-NBs present at later stages of
VZV infection sequestered ORF23 protein or possibly newly
assembled NCs with surface ORF23 protein and might differ from
the PML-NBs that modulate virus-cell interactions shortly after
herpesvirus entry [55].
VZV Nucleocapsids Are Sequestered in Endogenous
Nuclear PML Cages
We next used cryoimmuno-electron microscopy (cryoimmuno-
EM) to determine with ultrastructural precision whether the
ORF23 protein that was associated with PML-NBs represented
assembled NCs retained within these nuclear bodies or consisted
of ORF23-PML protein co-aggregates. This question was of
interest because PML has been observed to be associated with
aberrant protein aggregates, termed nuclear aggresomes [56] or
clastosomes [44] and with capsid proteins of other nuclear
replicating viruses, including papillomavirus [57,58], the neuro-
tropic JC virus [59] and HSV-1 [60]. Except for the HSV-1 study,
these analyses showed association of PML and capsid proteins by
confocal light microscopy which does not optically resolve
individual virion capsids; however some NC-like structures
appeared to be associated with PML gold labeling in HSV-1
infected cells by immuno-EM [60].
Our experiments to detect both PML and ORF23 protein at
ultrastructural resolution were first done with the Tokuyasu
method which allows single and double-immunogold labeling of
ultrathin (50–80 nm) cryosections with exquisite sensitivity [61–
63]. These results were then correlated with patterns of PML and
ORF23 protein localization observed by confocal microscopy
(Figure 2). By cryoimmuno-EM, endogenous PML-NBs in
uninfected cells were electron-dense subnuclear domains that
exhibited extensive PML gold labeling, consistent with the
punctate PML pattern seen by confocal microcopy (Figure 2A).
In VZV infected cells, cryoimmuno-EM revealed VZV NCs of
about 100 nm diameter (Figure 2B, arrow) that were abundantly
labeled with antibody to ORF23 protein, confirming its predicted
location on the capsid shell [54,64,65]. The viral NCs most likely
corresponded to the tiny ORF23-expressing punctae seen in the
nuclei of infected cells by confocal microcopy (Figure 2B, left
panel). Furthermore, cryoimmuno-EM revealed clusters of VZV
capsids that were surrounded by PML gold labeling (Figure 2C,
right panel) and double-immunogold labeling proved the spatial
association of PML protein (15 nm gold labeling) with individual
NCs and clusters of VZV NCs detected with antibody to ORF23
protein (10 nm gold labeling) (Figure 2D). Therefore, the co-
localization of PML-NBs and ORF23 protein detected by confocal
microscopy (Figure 1 and Figure 2C, left panel) resulted from the
sequestration of newly assembled VZV capsids in PML-NBs rather
than from the formation of PML-ORF23 protein aggregates.
To define the ultrastructure of PML subnuclear domains
harboring VZV NCs even more precisely, high-pressure freezing
and freeze-substitution was used to optimally preserve both cell
morphology and proteins [66] in uninfected and VZV infected
HELF (Figure 3 and Figure S3). Again, endogenous PML-NBs in
uninfected cell nuclei showed PML-specific labeling and were
electron-dense (Figure 3A). In VZV infected cells, individual
mature NC, which were identified by their dark electron-dense
centers, as well as immature NCs, were associated with varying
amounts of PML-positive fibrous material (Figure 3B and Figure
S3). Furthermore, clusters of NCs were observed within cage-like
structures that had dense PML-specific labeling (Figure 3C and
Figure S3). These PML cages consisted of concentrically arranged
protein fibers that tightly enclosed mature and immature NCs.
Thus, the sequestration of virion capsids within PML subnuclear
domains was confirmed with a second ultrastructural method.
Furthermore, the presence of fibrous PML cages that entrapped
both mature and immature herpesvirus capsids was demonstrated
for the first time because of better contrast and superior
ultrastructural preservation achieved with high pressure freezing
and freeze-substitution.
Validating observations from EM studies requires quantitative
analysis [67]. Examination of 30 VZV infected nuclei revealed
that about 80% (N=1,611) of all PML-specific gold particles were
associated with viral NCs (Figure 3D). The concentration of NCs
(number of NCs/mm
2) within PML subnuclear domains was
nearly 40 times higher than in other nuclear areas (Figure 3E),
proving that PML and VZV capsids were highly co-enriched
within PML-NBs and free PML protein was rare elsewhere in
infected nuclei. In infected nuclei that contained endogenous
PML-NBs an average of 62%65 SEM (N=30 nuclear profiles) of
VZV NCs was sequestered in PML-NBs. The proportion of
sequestered NCs (among all NCs present in an infected nucleus)
was higher when more PML protein was assembled to PML cages
and correlated positively with the amount of endogenous PML
protein present in the infected cell nucleus, measured as the PML
protein density (PML-gold/mm
2) (Figure 3F). Importantly, the
clusters of VZV NCs in these PML structures differed from the
paracrystalline arrays of NCs that form nuclear inclusions in HSV-
1 infected cells (compare Figure 3 and Figure S3 with Figure S4).
Thus, the ultrastructural analysis unequivocally identified the
association of both mature and immature virion capsids with PML
protein in the nucleus and NCs were usually confined within
endogenous cages consisting of PML-positive protein fibers in cells
infected with VZV in vitro. Furthermore, these results demonstrat-
ed that immunogold EM is the method of choice to show the
distribution of PML in infected nuclei unequivocally, including
demonstrating the presence of PML on some individual NCs, that
may be difficult to image by standard confocal microscopy.
Immunogold EM has the significant advantage that individual
Figure 1. Endogenous PML-NBs colocalize with ORF23 capsid protein in VZV infected cells. (A) Uninfected human embryonic lung
fibroblasts (HELF) were immunostained for SP100 (red) or PML (green) to visualize PML nuclear bodies (PML-NBs). Nuclei were stained with Hoechst
(blue). (B) HELF cells were infected with cell-associated VZV for 24 hr and immunostained for PML (green) and ORF23 (red). PML-NBs and ORF23
capsid protein colocalized (white arrows) in HELF infected with either VZV (left panel) or VZV expressing red fluorescent protein (RFP)-tagged ORF23
(right panel). Nuclei were stained with Hoechst (blue). ORF23 capsid protein was identified in 94% (N=228) of PML-NBs that were present in VZV
infected cells at 24 hr. Scale bars in A and B are 5 mm. (C) Quantitation of the mean number of PML-NBs in nuclei of uninfected HELF (N=180) and in
infected HELF cells at 48 hr after infection (N=180). The graph shows the mean 6 SD; asterisks indicate a significant difference (p,0.0001).
(D) Immunoblot analysis of PML protein (upper panel), VZV IE63 protein as a marker of VZV infection (middle panel) and tubulin (lower panel) in
whole cell lysates of HELF that were mock-infected or infected with VZV (rOka) for 48 hr. (E) Quantitation of the mean size (diameter in mm) of PML-
NBs in uninfected HELF and infected HELF. The box and whiskers plot shows the mean, 25 and 75 percentiles and the range of PML-NB sizes from 100
uninfected or infected nuclei, respectively; asterisks indicate a significant difference (p,0.0001).
doi:10.1371/journal.ppat.1001266.g001
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that allows a very wide range of labeling densities within the same
section to be imaged and quantified accurately.
PML Cages Sequester Nucleocapsids During Infection of
Human DRG and Skin Xenografts In Vivo
Since mature herpesvirus NCs must egress from the nucleus and
undergo secondary envelopment in the cytoplasm before infectious
virus release from the host cell [22], the sequestration of VZV NCs
by endogenous PML cages suggested a novel mechanism by which
PML might restrict viral replication and spread. However, this
observation might reflect a phenomenon unique to cultured cells
because VZV is known for its poor replication in vitro. Therefore,
we next explored whether this cellular response also occurred in
the differentiated neurons and satellite cells of sensory ganglia that
are targeted during acute VZV infection in vivo [30] and when
VZV reactivates from latency in neurons [68–70]. For these
experiments, human DRG xenografts in SCID mice were infected
for 14 days (acute phase of VZV infection [36]) and then harvested
and processed for semithin (500 nm) cryosectioning and confocal
microscopy or cryoimmuno-EM.
Numerous small PML-NBs (,1 mm) were detected in the nuclei
of neurons and satellite cells in uninfected DRG by confocal
microscopy (Figure 4A). In contrast, in infected neural cells, PML-
NBs were either dispersed or reorganized such that only one or
two enlarged structures were present; the mean diameter was
(1.9 mm60.8 SD; N=62). These structures were often ring-
shaped and exhibited intense enrichment of ORF23 protein in
their interior (Figure 4B–D). ORF23 protein was present in a
majority but not all (87%, N=116) of the ring-shaped PML-NBs
in VZV-infected neural cells. Ultrastructural studies revealed that
these large PML-NBs consisted of spherical PML cages containing
numerous sequestered viral NCs, as demonstrated by cryoim-
muno-EM with PML-specific labeling (Figure 4E).
VZV also targets skin for replication, creating cutaneous lesions
from which the virus is transmitted during varicella or herpes
zoster [30]. To determine whether NC sequestration by PML-NBs
also occurred in skin cells, skin xenografts were infected for 21
days, harvested and processed for paraffin-sectioning and confocal
microscopy. Like uninfected neural cells, uninfected skin cells
contained numerous small (,1 mm) PML-NBs (Figure 5A).
However, very large ring-like PML-NBs were observed in the
nuclei of infected cells that formed the typical VZV polykaryons
and expressed the VZV glycoprotein gE on plasma membranes
(Figure 5B); their mean diameter was 1.5 mm60.3 SD (N=81).
Importantly, as observed in VZV infected human DRG cells, the
ORF23 capsid protein was enriched in many of these large PML-
NBs in infected skin cells (Figure 5C and D).
These experiments established that endogenous PML formed
spherical nuclear cages containing VZV NCs not only in cultured
cells in vitro, but also in differentiated human cells infected in vivo.
Since neural and skin cells are targeted during VZV pathogenesis,
we hypothesized that PML cages might play a role in the intrinsic
host defense against VZV. These findings provided a rationale to
further investigate the molecular mechanisms of this cellular
response and to assess whether it could interfere with production
of infectious virus progeny.
Only the PML IV Isoform Promotes the Sequestration of
VZV Capsids in Nuclear PML Cages
PML protein exists in several isoforms that have unique C-
terminal domains resulting from alternative splicing of the PML
gene [14]. To define the process of NC sequestration in PML
cages during VZV infection and to ask if this process might
function as an intrinsic antiviral host defense, we evaluated six
major PML isoforms, PML I, II, III, IV, V and VI. These
experiments investigated whether exogenous expression of a
Figure 2. VZV nucleocapsids are sequestered in endogenous
nuclear PML cages. HELF cells were uninfected (A, left panel) or
infected (B, C, left panels) with VZV (rOka) for 48 hr and analyzed by
confocal immunofluorescence (IF) microscopy after staining for PML
(green) or ORF23 (red). For cryoimmuno-EM, HELF cells were uninfected
(A, right panel) or infected (B–C, right panels; D, left and right panels)
with VZV (rOka) for 48 hr and analyzed after immunogold labeling of
PML (15 nm) or ORF23 (10 nm) by transmission electron microscopy
(TEM). (A) PML-NBs visualized by confocal IF and by cryoimmuno-EM.
Dense clusters of PML-specific gold particles (15 nm) label PML-NBs,
indicated by arrowheads. (B) Tiny fluorescent punctae detected in VZV
infected nuclei immunostained for ORF23 (red) by confocal IF may
correspond to nucleocapsids (NCs). Cryoimmuno-EM identifies ORF23
(arrowheads) with NCs (arrows) by ORF23 specific gold-labeling of ring-
like or hexagonal structures of about 100 nm diameter. (C) PML (green)
and ORF23 (red) colocalize in PML-NBs shown by confocal IF
microscopy. Cryoimmuno-EM in combination with PML-specific single-
immunogold labeling (C, arrowheads) or double-immunogold labeling
for PML and ORF23 (D, left panel) identifies clusters of VZV NCs (arrows)
surrounded by PML protein. At a higher magnification (D, right panel)
of the cluster indicated by the black square, NCs with ORF23-labeling
(small arrowheads) and associated PML-labeling (large arrowheads) can
be seen. Scale bars in IF images are 5 mm. Scale bars for EM images are
as indicated.
doi:10.1371/journal.ppat.1001266.g002
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PLoS Pathogens | www.plospathogens.org 5 February 2011 | Volume 7 | Issue 2 | e1001266Figure 3. PML cages sequester mature and immature VZV nucleocapsids. (A-C) Representative immunogold-EM images of uninfected (A) or
VZV-infected (B and C) HELF cells at 48 hr after infection and processing by high-pressure freezing (HPF) and freeze substitution (FS) to optimally
preserve ultra-structural details. PML protein is specifically labeled with (A) 15 nm or (B and C) 10 nm gold particles (arrowheads indicate PML gold
particles). Arrows indicate examples of viral NCs. (A) PML-labeled endogenous NBs in uninfected cells; examples are shown in upper and lower panels.
(B) Individual VZV NCs (arrows) are associated with varying amounts of PML protein (arrowheads) as shown in the upper and lower panels.
(C) Clusters of VZV NCs (arrows) are sequestered in an endogenous fibrous PML cage (arrowheads). The black square in the upper panel demarks the
area (i) that is shown at higher magnification on the lower panel. Scale bars are as indicated. (D–F) Quantitative analysis of PML-specific gold particles
(N=1,611) and viral NCs (N=450) in 30 VZV-infected cell nuclei. (D) Percentage of the total number of PML-specific gold particles associated with VZV
capsids (black bar) or found ‘free’ within the nuclear area excluding PML-NBs (grey bar). (E) Density of viral NCs determined as NCs/mm
2 (mean 6 SD)
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distribution of ORF23 protein and sequestered VZV capsids.
PML-NBs were formed by the exogenously expressed isoforms
over the background of endogenous PML in uninfected and
infected cells (Figure S5). In control cells that were not transfected
but were infected with VZV, the ORF23 capsid protein showed no
redistribution if endogenous PML-NBs were completely dispersed
as happens in the majority of infected melanoma cells (Figure 6A,
upper panel; see also Figure S2A). When melanoma cells were
transfected with the PML isoforms and infected with VZV,
ORF23 protein was redistributed and colocalized with more than
95% (N=550) of PML-NBs only in cells that expressed PML IV
Figure 5. PML cages sequester VZV nucleocapsids during
infection of human skin. Human skin xenografts in the SCID mouse
model were collected 21 days after mock infection (A) or inoculation
with VZV (B–D). Thick (5 mm) paraffin sections were analyzed by
confocal IF microscopy after staining for PML (A), double-IF staining for
PML and the VZV glycoprotein gE (B) or double-IF staining for ORF23
and PML (C and D), as indicated at the right of each row of panels.
Nuclei are stained with Hoechst (blue). Images in A-C (left panels) are
overviews of the same skin sections, including epidermal and dermal
layers and hair follicles, after Hoechst staining (inverted grey scale). Blue
and red squares demark areas shown at higher magnification in the
panels on the right. Arrows indicate PML-NBs in the nuclei of skin cells.
(A) Uninfected skin cell nuclei contain several small PML-NBs (green).
(B) Infected cells have fused to form the syncytia (polykaryons). Large
ring-like PML-NBs (red) are visible and VZV glycoprotein gE (green) is
expressed on plasma membranes. (C) Large ring-like PML-NBs (green)
sequester ORF23 protein (red). (D) A single skin cell nucleus showing
PML-NBs (green) and ORF23 protein (red). All scale bars are 5 mm.
doi:10.1371/journal.ppat.1001266.g005
within PML-NBs (black bar) or within the nuclear area outside PML-NBs (white bar). (F) Correlation between the percentage of NCs sequestered within
PML-NBs (y-axis) and the PML labeling density in each nucleus, which is the number of PML-specific gold particles/mm
2 of the total nuclear area




Figure 4. PML cages sequester VZV nucleocapsids during
infection of human Dorsal Root Ganglia (DRG). Human DRG
xenografts in the SCID mouse model were collected 14 days after mock
infection (A) or inoculation with VZV (B–E) and fixed in 4%
paraformaldehyde. Semithin (500 nm) cryosections were analyzed by
confocal IF microscopy after staining for (A) Neural Cell Adhesion
Molecule (NCAM) and PML, or (B–D) ORF23 and PML, as indicated at the
right of each row of panels. Nuclei are stained with Hoechst (blue).
Images in A-C (left panels) show overviews of the same DRG sections
after Hoechst staining using an inverted grey scale. Blue or red squares
demark areas shown at higher magnification in the adjacent panels.
(A) Uninfected DRG sections show numerous small PML-NBs (red, white
arrows) in the nuclei of neurons (N) and satellite cells (s). (B, C) VZV
infected neurons and satellite cells with PML-NBs (white arrows) in
which PML (red) colocalizes with ORF23 capsid protein (green). Scale
bars are 5 mm. (D) Four examples (i–iv) of neural cells in infected DRG
with large ring-like PML cages (green, white arrows) that sequester
ORF23 protein (red). ORF23 capsid protein was present in 87% (N=116)
of PML-NBs within infected neural cells. Scale bars are 5 mm. (E) PML-
specific immunogold-labeling of ultrathin (80 nm) cryosections of
infected human DRG shows large ring-like PML cages (PML, 15 nm;
arrowheads) that sequester numerous VZV NCs (arrows) in infected
neural cells in human DRG. Areas in the black squares (i and ii) are
shown at higher magnification in panels at the right. Sizes of scale bars
are as indicated.
doi:10.1371/journal.ppat.1001266.g004
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isoforms recruited ORF23 protein to PML-NBs (Figure 6B and
Figure S5).
Photo-bleaching experiments with cells that expressed EGFP-
tagged PML IV and that were infected with recombinant VZV
expressing RFP-tagged ORF23 protein, revealed the striking
immobilization of ORF23 protein within EGFP-PML IV-NBs.
Even 45 min after photo-bleaching, RFP-ORF23 remained
confined to PML IV-NBs (Figure S6), indicating that PML IV
may form a physical barrier that constrains the mobility of ORF23
capsid protein and possibly of assembled capsids in the
nucleoplasm. Therefore we next analyzed VZV infected cells
expressing EGFP-tagged PML IV protein by immuno-EM to
determine whether VZV capsids were confined in PML cages
(Figure 6C). A quantitative analysis of 100 infected cell nuclei
showed that more than 90% of VZV NCs (N=4,900) were
sequestered (Figure 6C) whereas other nuclear areas were
essentially devoid of NCs, demonstrating a highly efficient
retention of NCs in PML IV-NBs.
Furthermore, like endogenous PML cages, the exogenous PML
IV cages (PML IV cages that formed in cells with endogenous
PML and over-expressed PML IV) in VZV infected cells did not
colocalize with the viral DNA replication compartments identified
by IE62 and ORF29 protein expression or in situ hybridization for
viral genomic DNA (Figure S7A–C). These experiments also
demonstrated that ORF23 protein recruitment was specific, as
compared to IE62 and ORF29 proteins, which showed no
redistribution by PML IV.
ORF23 Capsid Protein Interacts with PML IV in the
Absence of Other Viral Proteins
Having shown that PML IV reorganized the nuclear distribu-
tion of ORF23 protein and sequestered NCs into large PML-NBs
during VZV infection, we next investigated whether ORF23
protein was a molecular target of PML IV. ORF23 protein was
considered a likely candidate for recognition by PML IV because,
like the related HSV-1 VP26 small capsid protein [64,65], ORF23
protein may decorate the capsid surface on hexons formed by the
major capsid protein and is therefore likely to be accessible on NC
surfaces. This prediction was supported by the dense ORF23-
specific gold-labeling observed at the outer edges of VZV NCs
(Figure 2B).
When expressed in melanoma cells, untagged ORF23 protein
or ORF23 protein tagged with maltose-binding protein (MBP)
protein was found to be distributed diffusely in both the cytoplasm
and nucleus (Figure 7A). However, when cells were transfected
with plasmids expressing PML IV, both ORF23 protein and
MBP-tagged ORF23 protein were highly enriched within PML
Figure 6. PML IV promotes the sequestration of VZV nucleo-
capsids within PML cages. (A) Representative IF-microscopy images
show colocalization of PML IV-NBs (green) with ORF23 capsid protein
(red) in VZV-infected melanoma cells at 48 hr after infection. Cells were
either untransfected (control, upper panels) or transfected with
plasmids expressing PML IV (middle panels) or EGFP-PML IV (lower
panels). Nuclei were stained with Hoechst (blue). Arrows depict
examples of PML IV bodies. (B) Quantitation of the percentage of
PML-NBs that colocalize with ORF23 protein at 48 hr after infection of
cells that had been transfected with plasmids expressing the six
different PML isoforms, PML I-PML VI as indicated. Data shown for each
PML isoform represent the mean percentage 6 SD from five different
samples with at least 100 PML-NBs each. (C) Representative immuno-
gold-EM images after transfection with EGFP-PML IV and 48 hr after
VZV infection. PML protein was identified with a polyclonal (rabbit) anti-
PML antibody and Protein-A conjugated with 15 nm gold particles
(small arrowheads). Three areas (i-iii, black squares) are shown at higher
magnification. Arrows indicate viral NCs within densely labeled PML-
NBs. Quantitative EM analysis of 100 infected nuclei showed that more
than 90% of VZV NCs (N=4,900) were sequestered in PML cages. EM
scale bars are indicated.
doi:10.1371/journal.ppat.1001266.g006
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tegument protein [71,72], was used as an MBP-tagged control; it
was not recognized by PML IV and did not colocalize with PML
IV-NBs (Figure 7B, lower panels). The specific interaction of PML
IV with MBP-ORF23 protein but not with MBP-ORF4 protein
was confirmed by coimmunoprecipitation (Figure 7C). These data
showed that ORF23 protein was recruited to PML IV-NBs in the
absence of other VZV proteins. Therefore ORF23 protein is a
potential molecular target on NC surfaces that may physically
interact with PML IV during infection.
The Unique C-Terminal Domain of PML IV Is Necessary for
PML-mediated Sequestration of VZV Nucleocapsids
The unique C-terminal domain of PML IV, which is encoded
by exons 8a and 8b of the PML gene, differentiates this isoform
from the other five PML isoforms that failed to sequester NCs
[14]. We therefore asked whether expression of truncated PML IV
protein that had a deletion of exon 8b (PML IV-D8B) or of both
exons 8a and 8b (PML IV-D8AB) would eliminate the redistribu-
tion of ORF23 protein or capsids to PML cages. EGFP-tagged
PML IV-D8B or PML IV-D8AB continued to form PML-NBs
when exogenously expressed in VZV infected cells (Figure 8A).
However ORF23 protein no longer colocalized with these mutant
PML-NBs (Figure 8A and B), suggesting that the truncated PML
IV proteins could not promote NC sequestration. PML I and the
truncated PML I-D9 protein, lacking the unique PML I C-
terminus encoded by exon 9, were included as controls and also
failed to cause redistribution of ORF23 protein (Figure 8B). We
next investigated whether these results could be reproduced using
stable melanoma cells lines that avoided EGFP-tagging and
expressed untagged PML IV or PML IV-D8AB protein under the
control of a doxycycline-inducible promoter (Figure 8C and Figure
S8). These recombinant cell lines expressed similar amounts of
PML IV and PML IV-D8AB protein at 24 hr after induction with
5 mg/ml doxycycline and formed PML-NBs that were similar in
size (Figure S8A and B) and fewer than 0.5% cells exhibited
apoptosis based on Annexin V staining (Figure S8C). When the
induced cell lines were infected with VZV, ORF23 protein
colocalized completely with PML IV at 24 hr after infection
whereas ORF23 protein was not redistributed to PML-NBs in cells
that expressed the truncated PML IV-D8AB (Figure 8C), again
demonstrating that PML-NBs composed of truncated PML IV
were deficient in the sequestration of ORF23 protein, presumed to
be on VZV capsids.
To test this assumption, quantitative immuno-EM was used to
show patterns of NC distribution in cells induced to express PML
IV or PML IV-D8AB. For this purpose, samples were processed
with high-pressure freezing and freeze-substitution to optimally
preserve the ultrastructure of PML cages and virion capsids and to
achieve sensitive detection of PML protein by immunogold
labeling. Large spherical PML cages that harbored VZV NCs
were readily observed in cells expressing PML IV (Figure 9A, left
panel, and Figure 9B) and all PML IV cages entrapped both
Figure 7. PML IV binds ORF23 capsid protein in the absence of
other viral proteins. (A) Representative IF images show the cellular
distribution of either untagged ORF23 (red; left panel) or maltose
binding protein (MBP)-tagged ORF23 (red; right panel) at 48 hr after
transfection of melanoma cells. (B) IF localization of untagged ORF23
protein (red; upper panels), MBP-tagged ORF23 protein (red; middle
panels) or MBP-tagged ORF4 protein (red; lower panels) and PML IV
bodies (green, white arrows) at 48 hr after transfection of melanoma
cells. Nuclei were stained with Hoechst (blue). All scale bars are 5 mm.
(C) Coimmunoprecipitation (Co-IP) of PML IV using an anti-MBP
polyclonal (rabbit) antibody in cells co-transfected with PML IV
expression plasmid and MBP-ORF23 or the control MBP-ORF4, in the
combinations as indicated by ‘+’ and ‘-’. Co-IP of mock-transfected cells
(no PML IV overexpression) is shown in the lane at the far right. PML IV
was identified by immunoblotting with a polyclonal (rabbit) anti-PML
antibody. Western blot of the lysates confirmed the expression of
transfected PML IV, MBP-ORF23 and MBP-ORF4 (lower panel).
doi:10.1371/journal.ppat.1001266.g007
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Figure S9A–C). In contrast, PML IV-D8AB-NBs rarely seques-
tered any NCs even though numerous NCs were present in the
infected cell nucleus (Figure 9A; right panel). Infected nuclei
without any PML cages usually contained numerous randomly
scattered NCs (Figure S9A; compare left and right panels).
The mean size of PML cages in infected cells induced to express
PML IV was 1.6 mm 60.5 SD (N=100), which was similar to the
sizes of PML cages in neural cells (1.9 mm 60.8 SD; N=62) and
skin cells (1.5 mm 60.3 SD; N=81) in human tissue xenografts
that were infected with VZV (Figures 4 and 5). However, PML IV-
D8AB structures were significantly smaller than PML IV-NBs
(1.2 mm 60.4 SD vs. 1.6 mm 60.5 SD; p,0.0001; N=100) and
had a more compact appearance than PML IV-NBs, presumably
because fewer capsids were sequestered in these mutant PML-
NBs. However, large PML IV cages that were only partly filled
with sequestered NCs were also readily observed (Figure 9B)
indicating that size and architecture of PML IV cages is not only
determined by the sequestered cargo, but also by the assembly
properties of PML-positive fibers itself. Thus, truncation of the
unique C-terminal domain of PML IV influenced sequestration of
NCs and the overall architecture of PML-NBs.
Analysis of PML IV cages by TEM at high magnification
revealed a shell structure consisting of PML-positive fibers that
appeared to form a physical barrier entrapping VZV capsids
(Figure 9B); NCs were often aligned along the inner side of the
fibrous shell. PML IV cages were morphologically similar to the
endogenous PML cages found in VZV infected HELF in vitro
(Figure 2 and Figure 3) and in neural cells in vivo (Figure 4E).
Importantly, the thin PML-positive fibers exhibited rather weak
electron density (Figure 10B) and could only be identified
unequivocally by high magnification and after PML-specific
immunogold-labeling (Figure S9B and C). Therefore, despite their
size, these PML structures would be easily be missed in virus-
infected cells analyzed by morphological criteria only.
Quantitative analysis of NC distribution confirmed that PML
IV cages in infected inducible cell lines were highly efficient in
sequestration with more than 95% of NCs (N=5,938) being
retained in these structures (Figure 9C). In marked contrast, only
15% of NCs (N=4,395) were found within PML-NBs in cell lines
induced to express PML IV-D8AB (Figure 9C). The density of the
packing of NCs within individual PML cages was also significantly
higher in PML IV-expressing cells than in cells expressing PML
IV-D8AB, suggesting that PML IV cages had more capacity to
sequester NCs than those formed by truncated PML IV
(Figure 9D). Furthermore, the total number of NCs was signifi-
cantly higher (approximately 20%) in cells with PML IV cages
compared to those with PML IV-D8AB-NBs (p,0.0001),
indicating that NCs accumulated in PML IV-NBs (Figure 9E).
Herpesvirus capsids may be abortive (A type), intermediate
(B type) or mature (C type) containing viral DNA genomes [73].
To determine whether NC assembly or packaging was effected by
PML IV and if NC sequestration by PML IV cages was selective
for a specific type of capsids, the relative proportion of the three
major capsid types was quantified in nuclei expressing PML IV or
PML IV-D8AB-NBs, as well as in PML IV cages (Figure 9F).
Analysis of 5,938 NCs in 100 nuclei of cells expressing PML IV, of
4,395 NCs in 100 PML IV-D8AB expressing cells and of 5,829
NCs within PML IV cages, respectively, revealed similar
proportions of all NC types; 16–20% of all NCs were mature,
76–79% were intermediate and 4–5% were abortive in each cell
line and in PML cages (Figure 9F). This finding suggests that
expression of PML IV did not increase the proportion of abortive
or intermediate NCs compared to PML IV-D8AB expressing cells
Figure 8. Sequestration of ORF23 capsid protein requires the
C-terminal domain of PML IV. (A) Representative IF images show
that EGFP-PML IV (green; upper panels) colocalized with ORF23 protein
(red) but not with the C-terminal deletion mutants, EGFP-PML IV-D8B
(green; middle panel) or EGFP-PML IV-D8AB (green; lower panel) in
transfected cells that were infected with VZV for 48 hr. Nuclei were
stained with Hoechst (blue). Arrows indicate the location of PML-NBs.
Scale bars are 5 mm. (B) Quantitation of the percentages of PML-NBs
that colocalized with ORF23 protein in infected cells that expressed the
indicated PML isoforms or PML deletion mutants after transfection. The
bars show PML-NB colocalization with ORF23 as the mean percentage
6 SD for each PML isoform or deletion mutant from seven different
areas, each of which contained 60-120 PML-NBs. (C) Doxycycline-
inducible melanoma cells were generated that expressed no exogenous
PML IV (left), PML IV (middle) or the truncated mutant PML IV-D8AB
(right). The stable cell lines were induced with 5 mg/ml doxycycline and
then infected with VZV for 24 hr. Cells were immunostained for PML
(red) and ORF23 capsid protein (green); nuclei were stained with
Hoechst (blue). White arrows indicate PML-NBs. Scale bar, 5 mm.
doi:10.1371/journal.ppat.1001266.g008
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response against VZV by targeting all three types of NCs that are
made in the infected cell nucleus for entrapment.
PML IV Has Antiviral Activity against VZV that Requires
the Unique PML IV C-Terminal Domain
Since PML IV restricted NCs to PML cages, we hypothesized
that PML IV would impair the production of infectious virus.
Conversely, we predicted that infectious virus yields would be
unaffected in cells expressing the truncated PML IV-D8AB
mutant, which does not recruit VZV capsids (Figures 8 and 9).
Since VZV is highly cell-associated in vitro [74], viral replication is
measured by plaque assays using infected cells as the inoculum.
Given the critical importance of cell-cell spread for VZV infection,
our objective was to assess the infectivity of VZV infected cells with
and without PML-IV cages based on the transfer of virus from
these cell populations to a permissive cell monolayer. We focused
our analysis on the 24 hr time point after VZV infection of PML
IV and PML IV mutant-expressing cells in order to avoid any
potential effect of PML expression on the induction of apoptosis
which could also reduce viral titers and because 24 hr is a late
stage of VZV replication in vitro when NCs are present. We used
two plaque assay methods to assess the antiviral activity of PML
IV. In the first method, cells were transfected with an EGFP
control, EGFP-tagged PML IV or PML IV-D8AB constructs,
infected with recombinant VZV expressing RFP-tagged ORF23
protein for 24 hr and separated into subpopulations by fluorescent
activated cell sorting (FACS). Only cells that emitted both green
(EGFP, indicating transfection) and red (RFP, indicating infection)
fluorescence were recovered and equal numbers of infected cells
that expressed EGFP, EGFP-PML IV or EGFP-PML IV-D8AB
were added to permissive cell monolayers and observed for plaque
formation (Figure 10A–C). Plaques generated from inoculum cells
that expressed PML IV were significantly reduced (p,0.0001) in
five independent experiments; plaque numbers were determined
in triplicate in each independent experiment. Plaque numbers
were about 50% lower when compared to infected cells expressing
PML IV-D8AB or the EGFP control (Figure 10A). Furthermore,
the mean diameter of plaques that were created by infected cells
expressing PML IV (0.95 mm
2 60.06 SEM; N=70) was
significantly smaller than plaques produced by PML IV-D8AB
expressing cells (1.46 mm
2 60.09 SEM; N=70) (p,0.0001). In
contrast, the number and size of plaques from cells expressing
PML IV-D8AB was very similar to the EGFP control (Figure 10A).
In the second method, the antiviral activity of PML IV was
tested using the stable cell lines expressing inducible PML IV or
PML IV-D8AB. These conditions avoided variables that might be
associated with EGFP tagging of PML or infection with the
recombinant virus in which ORF23 capsid protein was expressed
as an RFP fusion protein. Inoculum cells that expressed induced
PML IV and that were infected for 24 hr were added to permissive
cell monolayers and observed for plaque formation (Figure 10B).
Plaques generated from inoculum cells that expressed induced
PML IV were significantly reduced (p,0.0018, N=4) by about
50% when compared to infected cells expressing PML IV-D8AB
or to control cells.
Thus, PML IV exhibited antiviral activity against VZV in
transfected cells as well as in an inducible cell line and its antiviral
activity was confirmed to require the unique PML IV C-terminal
domain. The N-terminal region, which contains the RBCC/
TRIM domain and is common to all PML isoforms and is present
in the truncated PML IV mutant, was not sufficient for antiviral
activity against VZV. Impaired virus production in PML IV
expressing cells when compared to PML IV-D8AB and control
cells correlated with the capacity of PML IV cages to sequester
NCs as observed by immuno-EM. Conversely, the failure of the
truncated PML IV-D8AB protein to exhibit antiviral activity
correlated with impaired nuclear retention of NCs in VZV
infected cells. These data together with the quantitative EM data
that showed that more than 90% of NCs were present within PML
cages at 48 hr suggest that NC are stably and not transiently
contained in the PML IV cages.
Individual PML IV Cages Co-sequester Capsid Protein and
Huntington’s Disease Protein in VZV Infected Cells
Ring-shaped PML-NBs similar to the endogenous PML cages in
VZV infected neurons and satellite cells in human DRG and to
PML IV cages in vitro have been observed in neural cell nuclei in
neurodegenerative disorders associated with expanded CAG
repeats encoding polyglutamine (polyQ) tracts in the abnormal
gene product [41,43]. Of particular interest, PML IV, which
promotes VZV capsid sequestration has been reported to retain
and degrade mutant polyQ-expanded Ataxin7 and the Hunting-
ton’s disease protein (huntingtin or Htt) within ring-shaped PML
clastosomes in cortical neurons [44]. We therefore asked whether
the PML IV cages formed in our inducible melanoma cell lines
were functionally like PML clastosomes as determined by their
capacity to sequester GFP-tagged Htt [75]. We used the HttQ72
construct, which expresses the aberrant Htt protein with a 72
amino acid polyQ tract [75]. When PML IV cells were transfected
without induction, HttQ72-GFP was primarily distributed diffuse-
ly in the cytoplasm (Figure 11A); it was also detectable in nuclei at
higher levels of expression. This pattern changed dramatically
when the cells were induced to make PML IV; almost all HttQ72-
Figure 9. Quantitative ultrastructural analysis of PML IV cages with entrapped VZV nucleocapsids. (A) Cells induced to express PML IV
(left panels) or PML IV-D8AB (right panels) and infected with VZV for 48 hr were processed for immunogold-EM. PML-NBs were identified with a
polyclonal (rabbit) PML antibody and protein A conjugated to 15 nm gold particles. Areas in black squares (i and ii) are shown at higher
magnification. Arrows indicate mature (C-type) capsids. Arrowheads indicate PML-specific gold particles (15 nm). The size of scale bars is indicated.
(B) Cells induced to express PML IV and infected with VZV for 48 hr were embedded in Epoxy-resin. Ultrathin sections were surface-etched with
hydrogen peroxide before PML-immunogold-labeling (15 nm, arrowheads). A PML IV cage with sequestered VZV NCs is shown. Red lines demark the
outer and inner border of the spherical PML cage. PML-specific labeling (15 nm gold particles) is visible when the areas in the black squares (i and ii)
are examined at higher magnification. The shell of the PML cage consists of PML-positive fibers (i and ii, lower panels). NCs align along the inner
margin of the fibrous PML cage (area i). (C-E) Quantitative ultrastructural analysis of 100 nuclear profiles each in cells expressing PML IV (black bars) or
PML IV-D8AB (grey bars). The total number of NCs analyzed was N=5,938 in PML IV cells and N=4,395 in PML IV-D8AB cells. (C) Quantitation of the
number of VZV NCs shown as the percentage of the total NCs sequestered by induced PML IV (iPML-IV) and induced PML IV-D8AB (iPML IV-D8AB);
the asterisks indicate a significant difference (p,0.0001). (D) Quantitation of the density of viral NCs within PML IV-NBs or PML IV-D8AB PML-NBs
(mean 6 SEM) within unit areas of PML-NBs (NCs/mm
2) from an analysis of 100 PML-NBs (p,0.0001). (E) Comparison of the total number of VZV NCs
per nuclear profile in nuclei with PML IV cages and nuclei with PML IV-D8AB NBs (mean 6 SEM; p=0.0003). (F) Proportion of the three types of VZV
capsids within 100 nuclear profiles of cells induced to express PML IV or PML IV-D8AB and within PML IV cages. The left panel illustrates mature
infectious (C-type), intermediate (B-type) and abortive (A-type) NCs visualized by TEM; the relative percentage of each type is shown in the pie charts
(A-type: light gray; B-type: dark gray; C-type: black). The total number (N) of capsids analyzed is indicated in each pie chart.
doi:10.1371/journal.ppat.1001266.g009
Nuclear PML Cages Sequester Viral Nucleocapsids
PLoS Pathogens | www.plospathogens.org 12 February 2011 | Volume 7 | Issue 2 | e1001266GFP was redistributed into nuclear PML IV-NBs (Figure 11B).
This data confirmed observations about polyQ protein interac-
tions with PML IV [44] and showed that PML IV-NBs in
melanoma cells can sequester polyQ-tract proteins, as occurs in
neuronal PML clastosomes.
These experiments led us to consider whether PML IV cages
could co-sequester the ORF23 capsid protein marker, indicating
retention of VZV capsids, together with the mutant Huntington’s
disease protein. VZV infection of cells that were transfected with
HttQ72-GFP but not induced showed no change in the diffuse
cytoplasmic pattern of HttQ72-GFP suggesting that VZV
infection was not sufficient to redistribute this polyQ-protein
(Figure 11C). However, when PML IV expression was induced,
HttQ72-GFP was dramatically reorganized and colocalized in
PML-NBs together with the ORF23 capsid protein in infected
cells (Figure 11D). To our knowledge, these experiments
Figure 11. PML IV cages cosequester ORF23 capsid protein and
Huntington’s disease protein in VZV infected cells. PML IV
inducible cell lines were transfected to express HttQ72-GFP. (A) HttQ72-
GFP (green) expressing cells were fixed in the absence of PML IV
induction. (B) HttQ72-GFP (green) expressing cells were induced to
express PML IV and fixed after 48 hr. PML IV was detected by PML-
specific IF staining (red). Recruitment of HttQ72-GFP to PML IV bodies
(white arrows) is visible. (C) HttQ72-GFP transfected cells were infected
with VZV for 48 hr without induction of PML IV expression. IF-images
show the localization of HttQ72-GFP (green), PML (blue) and ORF23
capsid protein (red) in a syncytium (polykaryon) of fused VZV-infected
cells. (D) A HttQ72-GFP transfected cell (the cell on the right) after
induction of PML IV and infection with VZV for 48 hr. IF-images show
the colocalization (white arrows) of HttQ72-GFP (green), PML (blue) and
ORF23 capsid protein (red).
doi:10.1371/journal.ppat.1001266.g011
Figure 10. PML IV requires the unique C-terminal domain for
inhibition VZV replication. (A) VZV plaque assay with melanoma
cells that were transfected either with EGFP control, EGFP-PML IV or
EGFP-PML IV-D8AB expression constructs and infected for 24 hr with
VZV (rOka-RFP-ORF23) that expressed RFP tagged capsid protein. Only
cells that were both transfected (green fluorescence) and infected (red
fluorescence) were recovered by FACS. Melanoma cell monolayers were
inoculated with equal numbers of cells from each of the sorted cell
preparations. (A) Plaques were counted after 72 hr. Data are shown as
the mean percentage (mean 6 SEM) of plaque numbers normalized to
the control (EGFP alone) from five independent experiments; plaque
numbers were measured in triplicate in each experiment. The asterisks
indicate a significant difference (p,0.0001). (B) Infectious virus
production 24 hr after VZV infection of doxycycline-induced control,
PML IV or PML IV-D8AB expressing cell lines, shown as mean plaque
numbers (percentage of control 6 SEM). The number of plaques
formed in cells expressing PML IV was significantly reduced compared
to the number in PML IV-D8AB expressing cells (p=0.0018; N=4).
doi:10.1371/journal.ppat.1001266.g010
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capacity to sequester both the aberrant poly-Q protein produced
in a neurodegenerative disease and a viral capsid protein
associated with NC entrapment in PML-NBs and that individual
PML cages can simultaneously target and sequester an aberrant
polyQ-protein and viral NCs.
Discussion
Diverse types of PML-NBs that are distinguishable by their size,
shape and dynamic behavior are found in mammalian cell nuclei
[4,5,11,18]. We identify a distinctive class of endogenous PML-
NBs that form large spherical PML cages in differentiated human
neural and skin cells infected with VZV in vivo. These endogenous
PML cages were found to sequester newly assembled mature and
immature viral nucleocapsids in the nuclei of infected neurons,
satellite cells and epidermal cells, and in cultured cells infected
with VZV in vitro.
Similar large PML cages that retained VZV NCs were formed
when the PML IV isoform was expressed in cultured cells in vitro
but not by PML isoforms I, II, III, V or VI. Importantly, PML IV
exhibited antiviral activity against VZV. The antiviral function of
PML IV was associated not only with a unique capacity to
sequester NCs but also to bind the ORF23 capsid surface protein.
All of these functions required the unique C-terminal domain of
PML IV. The N-terminal region, which is common to all PML
isoforms and contains the RBCC/TRIM domain [14] was not
sufficient for antiviral activity or NC retention. The antiviral
activity of PML IV was not likely to be explained by inhibition of
viral genome synthesis or packaging into capsids by PML IV since
the relative proportion of empty capsids was not increased in PML
IV expressing cells. PML IV-D8AB may lack the capacity to
produce PML-NBs with the architecture of those formed by intact
PML IV, rendering them ineffective for capsid entrapment. It is
also possible that the failure of PML-NB in PML IV-D8AB
expressing cells to entrap virions reflects in part a dominant
negative effect of PML IV-D8AB, preventing any endogenous
PML IV from interacting with the ORF23 capsid protein.
The correlation between PML-mediated antiviral activity,
capsid sequestration and ORF23 protein binding provides strong
evidence that PML cages constitute an intrinsic host defense
against this common herpesvirus. This role is supported by the
finding that human neural and skin cells infected with VZV in vivo
contained PML-NBs with the same distinctive morphology.
ORF23 capsid protein was recruited to these structures and they
consisted of cages formed by concentric rings of PML fibers
sequestering NCs. Notably, while VZV infection promoted the
dispersal of most PML-NBs, PML protein itself was not degraded,
indicating that PML nuclear cages, rather than free PML protein,
may be the primary obstacle to VZV replication.
How do NCs become entrapped within PML cages? Our
working hypothesis is that individual NCs are recognized by PML
protein (PML oligomers or fibers) through interactions with the
capsid surface. These initial interactions may result in recruitment
of more PML and NCs, thus growing into larger PML-NC
assemblies. Alternatively, although they were rare in our immuno-
EM studies, some aggregates of NCs may form spontaneously,
which are then recognized by PML and enclosed in PML cages.
Pre-existing, non-disrupted PML-NBs may also constitute a
favorable environment (a platform) for NC aggregation, as has
been proposed to account for the accumulation of aberrant
cellular proteins in PML-NBs in neurons [45]. These possibilities
are not mutually exclusive and a combination of all three may
occur in the infected cell nucleus when capsids are produced.
Most PML cages observed in VZV infected neural and skin cells
were significantly larger than the small PML-NBs that associate
with viral genomes and exert antiviral effects by interfering with
the initial transcription of herpesviral genes [76,77]. PML cages
were also more prominent later in infection, at the stage of viral
capsid assembly. A significant antiviral effect was predicted
because sequestration of abortive, immature and mature virions
into fibrous PML cages was highly efficient, leaving very few
mature capsids free to egress across the nuclear membrane to form
infectious particles in the cytoplasm. Thus, PML cages conferred
antiviral activity at a later stage of infection by a mechanism
completely different from PML suppression of early viral gene
transcription. These two PML-mediated antiviral mechanisms are
not mutually exclusive and would be expected to function
synergistically. The absence of PML cages may contribute to the
increase in VZV replication observed when PML protein was
depleted by RNA interference [31].
Our experiments provide the first evidence that a specific PML
isoform, PML IV, contributes to the cellular antiviral response by
promoting nuclear immobilization of herpesvirus nucleocapsids.
PML IV interacted specifically with the ORF23 capsid protein in
the absence of other VZV proteins. Since ORF23 protein was
expressed on NC surfaces, it offers a likely target for PML IV
recognition, as the first step leading to the retention of assembled
NCs in PML cages. PML IV, as well as PML III and PML V has
been reported to be expressed less abundantly than PML isoforms
I/II in some cell lines and primary cells in vitro [17]. However, the
pattern of PML isoform expression in vivo in human neural and
skin cells for which VZV exhibits tropism or when these cells
become infected with VZV is not known. We propose that PML
IV may act as a potent modulator of PML-NB architecture, since
others have also observed that exogenous PML IV (expressed
along with endogenous PML) promotes the formation of large
spherical PML-NBs [44]. As noted, PML cages that formed upon
overexpression of PML IV together with endogenous PML in vitro
best mimicked (both structurally and functionally) those endoge-
nous large PML cages observed in neural and skin cells infected
with VZV in vivo and both sequester NCs with ORF23 capsid
protein. If PML IV is not abundant in the small PML-NBs of
uninfected neurons, satellite cells or epidermal cells, the ratio of
PML isoforms may change upon infection, PML IV may become
more abundant or specific modifications on PML isoforms may be
altered when these differentiated cells are infected or otherwise
stressed. It was apparent that PML-NBs exhibited a striking
reorganization from multiple small compact structures to a few
large ring-shaped cages upon VZV infection in human tissues,
which could be consistent with changes in the ratio of PML
isoforms and upregulation of PML IV. Of particular interest, PML
IV transcription was upregulated when cultured cells were
stimulated with type I IFN [44], neurons have been shown to
produce type I IFN during viral infection [78] and the IFN
pathway is upregulated dramatically in human tissues infected
with VZV in vivo [39]. Taken together, our findings point to the
need to better understand the patterns and regulation of the tissue
specific expression of PML isoforms and their functions in virus-
infected cells. For example, different PML isoforms might
recognize the outer capsid proteins of other herpesviruses or
nuclear replicating DNA viruses and retain NCs, causing antiviral
effects when a specific PML isoform is either not degraded
efficiently or its production is induced in the infected cell.
Since the intranuclear mobility of herpesvirus NCs via actin
filaments may facilitate formation of NC assembly domains and
NC transport to the nuclear membrane [79,80], we suggest that
PML-mediated entrapment of NCs is likely to prevent NC
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membrane. This hypothesis is supported by our observation that
the number of intranuclear NCs was significantly higher in cells
with functional PML IV cages as compared to control cells.
An intrinsic defense mechanism in which PML binds to a viral
capsid protein and sequesters NCs obviously depends on the
persistence or new synthesis of PML protein in the infected cell
nucleus at the stage of capsid assembly, which occurs in VZV
infected cells but not in HSV infected cells. Since HSV-1 degrades
PML protein shortly after virus entry and shuts off host cell protein
synthesis [25–27], both the early effects of PML on viral gene
expression and this later antiviral activity would be expected to be
counteracted. Some PML-specific gold labeling associated with
NC-like structures, although not in PML cages, has been reported
in HSV-1 infected cells at late times [60]. Overexpression of PML
as a 69 kDa protein did not inhibit HSV-1 infection and PML
cages were not observed but the PML isoform was not
unequivocally identified [81]. Of interest, other nuclear replicating
DNA viruses, including papillomavirus and JC (polymoma) virus
also have limited capacity to degrade PML protein and PML
binding to their capsid proteins has been reported [57,59]. These
interactions were proposed to support infection by directing the
viral genome to replication compartments or facilitating virion
assembly but enhancing or inhibitory effects of specific PML
isoforms on viral replication could not be assessed [82,83].
Nevertheless, particular PML isoforms could have pro-viral
functions through some PML-capsid protein interactions and
antiviral consequences in others, as we observed here in VZV
infected cells.
Interestingly, stimulation of PML expression by type-I interfer-
on and PML-mediated sequestration and immobilization NCs of
VZV, a DNA virus, has parallels with the antiviral mechanism of
IFN-induced Mx-GTPases against RNA viruses. These proteins
also form oligomeric structures and inhibit the replication and
assembly of several negative-strand RNA viruses by sequestering
and immobilizing viral ribonucleocapsids or nucleocapsid protein
[84]. For example, the human MxA GTPase was found to
sequester the LaCrosse bunyavirus nucleocapsid protein into
fibrillar cytoplasmic complexes thereby inhibiting viral RNA
genome replication and the formation of enveloped virion particles
on membranes in the Golgi compartment [85,86]. Thus, these two
IFN-induced antiviral responses appear to depend on creating
intracellular structures that act as physical barriers during the later
viral assembly stage of infection.
Our observations of VZV NC sequestration in PML-NBs in
neurons, satellite cells and skin cells in vivo are relevant to a better
understanding of the control of VZV infection in the human host.
We suggest that the role of NC entrapment by PML cages in skin
is important for the modulation of the infection by the innate,
interferon-induced response through restriction of cell-cell spread.
Diverting a substantial majority of mature capsids to PML cages is
likely to regulate lytic VZV infection in vivo. In fact, this process
may benefit the virus since it is important for VZV and other
herpesviruses to achieve a well-balanced virus-host interaction.
Persistence of the virus in the human population requires a
relatively mild infection. An incapacitating infection of the host
that would limit opportunities for VZV transmission to susceptible
contacts and would hinder, rather than support the persistence of
the virus in the population as a whole. In addition to limiting skin
infection, the consistent finding of large PML cages in neuronal
cells of human DRG xenografts infected with VZV suggests the
possibility that this intrinsic host cell response might restrict
episodes of VZV reactivation from latency so that the episode
remains subclinical [33,87]. We hypothesize that when VZV
reactivates from latency in persistently infected neurons, trapping
newly formed NCs by PML cages would reduce the possibility for
spread of infectious virus particles down the axons to skin and
would also limit infection of adjacent satellite cells and neurons in
the DRG where reactivation is occurring. This process would
result in abortive VZV reactivation [88]. From a clinical
perspective, it is notable that patients treated with arsenicals have
an extremely high rate of clinically symptomatic herpes zoster, due
to VZV reactivation [89,90] and arsenicals are potent triggers of
PML degradation [91,92].
Since VZV is a human neurotropic virus, it is of interest that
ring-like PML-NBs similar in size to endogenous PML cages in
VZV infected neurons and satellite cells in DRG in vivo and PML
IV cages in vitro are found in neural cell nuclei in several neurode-
generative disorders [45]. Many of these disorders are associated
with expanded CAG repeats encoding polyglutamine (polyQ)
tracts, including Huntington’s disease and several types of
spinocerebellar ataxia and PML was associated with these protein
inclusions [40–43]. Importantly, the same PML isoform, PML IV,
which promotes VZV capsid sequestration has been reported by
others to form ring-like PML clastosomes that mediate the
sequestration and degradation of mutant polyQ-expanded Ataxin7
and Huntington’s disease protein (huntingtin or Htt) in cortical
neurons [44]. The morphological similarity between PML cages
found in VZV infected cells and these ring-like PML clastosomes
and the finding that PML IV can co-sequester ORF23 capsid
protein together with the Huntington’s disease protein in VZV
infected cells, suggest that the PML cages described here and PML
clastosomes are structurally and functionally related subnuclear
domains. Neurons are post-mitotic cells and need to safely contain
toxic proteins and/or increase their clearance, whether aberrant
host cell proteins or virion structures [46,50]. Of interest, aberrant
polyQ proteins tend to form large aggregates that like NCs may be
particularly resistant to the celluar mechanisms for degradation of
unwanted proteins and the nucleus may have limited capacity to
cope with misfolded proteins compared to the cytoplasm [75].
PML IV may specialize in restricting these degradation-resistant
structures to nuclear subdomains and limit their toxicity longer
term.
In summary, the efficient sequestration of virion capsids in PML
cages that contributes to the intrinsic antiviral host response
against VZV appears to be the outcome of a basic cytoprotective
function of this distinctive category of PML-NBs in safely
containing aggregation-prone aberrant proteins. Both aggrega-
tion-prone proteins and virion capsids are therefore potential
substrates for sequestration in these PML cages.
Materials and Methods
Ethics Statement
Human fetal tissues for SCID xenograft studies were obtained
from Advanced Bioscience Resources, Inc. (Alameda, CA) in
compliance with state and federal regulations for tissue acquisition
for biomedical research, in accordance with FDA 21 CFR Part
1271 GTP (Good Tissue Practices), UAGA and NOTA. Animal
protocols complied with the Animal Welfare Act and were
approved by the Stanford University Administrative Panel on
Laboratory Animal Care.
Cells and Viruses
Human lung embryonic fibroblasts (HELF) and a human
melanoma cell line (MeWo, ATCC number: HTB-65) were grown
in Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal bovine serum, nonessential amino acids (100 mM) and
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ml). HELF and the melanoma cell line (as obtained from ATCC)
were passaged less than 25 times.
VZV used in these experiments was recombinant Oka (rOka)
derived from the wild type low passage parent Oka strain (pOka).
VZV (rOka) and the recombinant rOka-RFP-ORF23 expressing
RFP-tagged ORF23 [54] were propagated in melanoma cells and
HELF cells [32]. Transfection was done with Lipofectamin 2000
(Invitrogen) for 14 hr. Viral infection was done with cell-associated
VZV at a ratio of 1/20 (infected cells/uninfected cells) for 24 or
48 hr.
Expression Plasmids
Plasmids pEGFP-PML (I-VI) [18] were gifts from Prof. Peter
Hemmerich, Leibnitz-Institute of Age Research, Jena, Germany.
Plasmid pcDNA3-PML IV [44] was generously provided by Prof.
Annie Sittler, Universite Pierre et Marie Curie, Paris, France. Plasmids
pCR3-MBP-ORF4, pCR3-MBP-ORF23 and pENTR207-ORF23
vectors have been described [93]. The plasmid pcDNA3-HttQ72-GFP
[75] was a kind gift from Prof. Ron Kopito, Stanford University,
Stanford, USA. Plasmid pCR3-ORF23 that expresses untagged
ORF23 was constructed using the pENTR207-entry vector and the
pCR3 destination vector with the LR Clonase II gateway cloning
reaction (Invitrogen). PML deletion constructs EGFP-PML I-D9,
EGFP-PML IV-D8AB and EGFP-PML IV-D8B were made as
follows: exon 9 was removed from PML I by PCR (primers PML ID9
59A/PML ID95 9Ba n dP M LI D93 9A/PML ID93 9B). pEGFP-CI
PML IV was the template used to delete exon 8b (primers PML
IVD8B 59A/PML ID95 9Ba n dP M LI V3 9A/PML IV 39B) and exons
8ab (primers PML IVD8AB 59A/PML IVD8AB 59Ba n dP M LI V
39A/PML IV 39B). pEGFP-C1 PML I was digested with MluI and a
6.1 kb vector DNA was isolated. pEGFP-C1 PML IV was digested
with BbvCI/MluI and a 5.6 kb vector DNA was isolated. Purified,
digested PCR products were ligated into the appropriate vectors to
generate pEGFP-PML I-D9, pEGFP-PML IV-D8AB and pEGFP-
PML IV-D8B. Primer sequences are listed in Table S1.
Construction of Inducible PML Expressing Melanoma Cell
Lines
Melanoma cells expressing doxycyline-inducible PML IV or
PML IV-D8AB were made using the pRetro-X-Tet-On-Advanced
vector system and pRetro-X-Tight-Pur plasmid (Clontech Labora-
tories) with the PML IV or PML IV-D8AB sequence derived from
the plasmid pcDNA3-PML IV [44]. The stable cells were induced
with 5 mg/ml doxycyline for 24 hr before infection with VZV.
Human Dorsal Root Ganglion (DRG) and Skin Cell
Xenografts
Human fetal DRG were inserted under the kidney capsule of
male CB-17
scid/scid mice (Taconic Farms, Germantown, NY),
inoculated with rOka-infected HELF and harvested after 14 days
[36]. Human fetal skin xenografts were inoculated with VZV
rOka-infected HELF and harvested after 21 days [34]. Human
tissues were provided by Advanced Bioscience Resources (ABR,
Alameda, CA) and were obtained in accordance with state and
federal regulations. Animal protocols complied with the Animal
Welfare Act and were approved by the Stanford University
Administrative Panel on Laboratory Animal Care.
Microscopy Analysis of Xenograft Tissue Sections and
Cultured Cells
DRG xenografts were prepared for cryosectioning as described
previously [88]. Human skin xenografts were embedded in
paraffin and 5 mm sections were prepared. For confocal
microscopy, sections were deparaffinized with tissue clearing agent
(‘‘Safeclear II’’, Fisher Scientific), rehydrated and antigen retrieval
was performed in citric acid-based antigen retrieval solution for
90 sec at 100uC. Sections were then blocked and immunolabeled
as described previously [88]. Cultured cells on glass coverslips
were fixed in 4% paraformaldehyde in PBS for 20 min at room
temperature or were fixed with methanol at -20uC for 10 min and
air-dried. Cells were blocked and immunostained as described
previously [32].
Antibodies and Confocal Immunofluorescence
Microscopy
Antibodies used for confocal microscopy were: rabbit polyclonal
anti-PML and mouse monoclonal anti-PML (PG-M3), rabbit
polyclonal anti-Sp100 (all Santa Cruz Biotech), mouse monoclonal
anti-N-CAM (Zymed), rabbit polyclonal anti-VZV-ORF23 [54],
rabbit polyclonal anti-VZV-IE62 and rabbit polyclonal anti-VZV-
ORF29 [32]. Antibodies for secondary detection were Alexa Fluor
488, Alexa Fluor 594 or Alexa Fluor 647 conjugated donkey anti-
mouse or donkey anti-rabbit antibodies (Invitrogen). Infected
tissues, cultured cells and PML-NBs were imaged and quantified
using a Leica TCS
SP2 confocal laser scanning microscope
(Heidelberg, Germany). Microscope objectives were 40/1.0
(Numerical Aperture, N.A.) or a 63/1.4 (N.A.) plan apochromate
objectives. Images were scanned at 102461024 pixels with at least
four times frame averaging and the pinhole adjusted to one airy
unit. Brightness and contrast were adjusted using Photoshop CS3
(Adobe) or iPhoto (Apple). The number of PML-NBs and
colocalization of PML-NBs with ORF23 protein were quantified
using captured digital images and the analysis and measurement
tools in Photoshop CS3 extended version (Adobe).
Electron Microscopy (EM)
Samples were either prepared for cryosectioning or high-
pressure frozen (HPF) and freeze substituted (FS) and then
embedded in either LR-white or Epoxy resin (Embed812).
Preparation and labeling of cryosections was done as described
previously [88]. Cells were high-pressure frozen in a Leica EM
PACT2. Frozen specimen carriers with cells were placed into
frozen cryovials containing acetone with 0.1% glutaraldehyde and
0.1% uranyl acetate (for LR White embedding) or in acetone with
1% osmium tetroxide and 0.1% uranyl acetate (for Epon
embedding). The frozen vials were placed into a Leica AFS for
the freeze-substitution procedure and then embedded in either
epoxy resin (Embed 812) or LR-White resin. Ultrathin (50–70 nm)
LR-white or Epon-sections were prepared with a diamond knife
(Diatome) using a ultramicrotome (Ultracut, Leica). For immuno-
gold-labeling of Epon-sections, these sections were first etched with
5% hydrogen peroxide for 5 min and then rinsed with distilled
water. Sections were pre-blocked in DIG-blocking solution
(Roche) for 30 min. Primary antibodies and Protein A-gold
particles were diluted in blocking solution and sections were
incubated for 1 hr or 30 min, respectively, at RT. Rabbit
polyclonal anti-PML antibody (Santa Cruz Biotech) and rabbit
polyclonal anti-ORF23 antibody were used at 1:10 dilution.
Finally the sections were stained with 3.5% aqueous uranylacetate
for five minutes and with 0.2% lead citrate for three minutes and
air-dried. Sections were analyzed using a JEOL 1230 transmission
electron microscope (TEM) at 80 kV and digital photographs were
taken with a GATAN Multiscan 701 digital camera. Quantifica-
tion of PML-specific immunogold-labeling and evaluation and
counting of virion capsids was done by analyzing captured digital
images with Photoshop CS3 (extended edition, Adobe) using the
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profiles and PML compartments. PML-labeling density (number
of gold particles per mm
2) and capsid density (number of capsids
per mm
2) were calculated with Microsoft Excel (2008). Statistical
analysis was performed using GraphPad Prism (version 5.0)
statistical software.
VZV Plaque Assays
For plaque assays after fluorescent activated cell sorting (FACS),
cells were transfected with pEGFP, pEGFP-PML IV or pEGFP-
PML IV-D8AB expression plasmids, infected for 24 hr with rOka-
RFP-ORF23 and sorted by FACS (Digital Vantage, BD
Bioscience). Cells that were both green (transfected) and red
(infected) were recovered, equal numbers were seeded onto
melanoma cell monolayers in triplicate and plates were incubated
for 72 hr. Plaques were visualized by standard methods; five
independent FACS experiments were performed. Plaque numbers
were counted and plaque sizes were determined from digital
photographs by calculating the area of .70 randomly selected
plaques per sample using Photoshop CS3 (extended edition,
Adobe). Virus plaque assays with inducible PML expressing cell
lines (Mel39-control, Mel39-PML IV and Mel39-PML IV-D8ab)
were done using cells induced overnight with 5 mg/ml doxycy-
cline, infected for 24 hr, harvested, serial diluted and seeded in
triplicate onto melanoma cell monolayers. Plaques were counted
and numbers expressed as percentages of the control; four
independent experiments were performed.
Immunoprecipitation (IP) and Western Blotting
For immunoprecipitation studies, samples were analyzed using
the ExactaCruz IP-Western Kit (Santa Cruz Biotechnology, Inc.),
according to manufacturer’s instructions. MBP-ORF23 or MBP-
ORF4 and PML IV transfected cells were grown in 75 cm
2 flasks
and lysed in 300 ml high salt buffer (20 mM HEPES [pH 7.2],
450 mM NaCl, 1.5 mM MgCl2, 0.5% NP-40, 20% Glycerol)
supplemented with EDTA-free protease inhibitor cocktail (Roche).
Cell debris was removed by centrifugation. The supernatant was
combined with 1,200 ml NaCl-free low salt buffer (20 mM HEPES
[pH 7.2], 1.5 mM MgCl2, 0.5% NP-40, 20% Glycerol) and
centrifuged again. 4 mg of anti-MBP monoclonal antibody (New
England Biolabs) was coupled to 100 ml sepharose beads. Beads
were washed in PBS and then incubated with 1,000 ml pre-cleared
cell lysate at 4u C for 4 hr. Beads were then washed six times with
the binding buffer (20 mM HEPES [pH 7.2], 90 mM NaCl,
1.5 mM MgCl2, 0.5% NP-40, 20% glycerol), boiled with SDS
sample buffer, and analyzed by Western blot using rabbit
polyclonal anti-PML antibody (1:2,000), anti-MBP antibody
(1:2,000). For Western Blot analysis of cultured cell lysates, cells
grown in 6-well plates were lysed in 150 ml high salt buffer (see
above). Whole lysates were then combined with 150 ml SDS
sample buffer and boiled for 5 min before loading on a 7.5% SDS
PAGE. MBP-tagged constructs of ORF23 were used in these
cotransfection and IP experiments because they yielded higher
expression levels and showed less cytotoxicity; the monoclonal
anti-MBP-antibody was more effective for IP than the polyclonal
ORF23 antibody.
Apoptosis Assay
The Vibrant Apoptosis Assay (Invitrogen) with Annexin V
conjugated to Alexa Fluor 488 was used to evaluate the percentage
of apoptotic cells at 24 hr after doxycycline induction of PML IV
and PML IV-D8AB expressing cell lines. Approximately 5,500
cells per cell line were evaluated by confocal microscopy.
Statistical Analysis
Student’s t tests were performed for all experiments using Graph
Pad Prism (version 5.0) statistical software. A p-value of ,0.05 was
considered statistically significant.
Supporting Information
Figure S1 Endogenous PML cages are distinct from VZV DNA
replication compartments.(A and B) HELF cells were infected with
VZV for 24 hr. (A) Viral replication compartments in infected cell
nuclei were shown by staining for IE62 (green) and the ORF29
single-strand DNA binding protein (red). These proteins coloca-
lized in viral replication compartments (yellow, merged images).
Nuclei were stained with Hoechst (blue). (B) Representative
examples of ring-shaped endogenous PML-NBs (green) and
VZV replication compartments (IE62, red). Nuclei were stained
with Hoechst (blue). The areas in the white squares (i and ii) are
shown at higher magnification in the adjacent panels. White
arrows indicate the location of ring like PML-NBs. Scale bars are
5 mm.
Found at: doi:10.1371/journal.ppat.1001266.s001 (1.45 MB TIF)
Figure S2 PML and ORF23 colocalize in VZV-infected
melanoma cells.(A) Representative fluorescent microscopy images
show PML-NBs (green) and ORF23 capsid protein (red) in
melanoma cells infected with VZV and examined at 24 hr post
infection. Nuclei were stained with Hoechst (blue). White arrows
indicate colocalization of PML-NBs and ORF23 protein. White
asterisks indicate infected cell nuclei in which PML-NBs have been
completely dispersed. (B) Quantitation of the mean number of
PML-NBs in the nuclei of uninfected (N=180) and infected
(N=180) melanoma cells (mean + SD) examined at 48 hr after
VZV infection. (C) Quantitation of the percentage of uninfected or
infected cells that contain PML-NBs at 48 hr post infection. Six
fields with 30 cells each were analyzed (mean + SD). (D) Western
blot analysis of PML protein, IE63 protein, which was used as a
marker of VZV infection, and tubulin in whole cell lysates of
melanoma cells that were mock infected or infected with VZV
(rOka) for 48 hr.
Found at: doi:10.1371/journal.ppat.1001266.s002 (2.43 MB TIF)
Figure S3 VZV Nucleocapsids (NCs) are associated with
endogenous PML-positive fibers. Representative VZV infected
HELF cells at 48 hr after infection, as seen after high-pressure
freezing, freeze substitution and embedding in LR-white for
immunogold-EM. PML protein was identified with a polyclonal
(rabbit) anti-PML antibody and Protein-A conjugated with 10 nm
gold particles (large arrowheads). Arrows indicate viral NCs. Small
arrowheads indicate PML-positive filamentous structures. VZV
NCs are associated with PML-positive meshwork (upper left),
PML fibers (lower left) or fibrous spherical PML cages (large right
panel).
Found at: doi:10.1371/journal.ppat.1001266.s003 (0.64 MB TIF)
Figure S4 Paracrystalline inclusion bodies of HSV-1 nucleocap-
sids. HSV-1 infected HELF were fixed and embedded in LR-white
for EM analysis at 24 hr after infection (MOI=0.1). The area in
the black square is shown at higher magnification in the right
panel and contains a representative paracrystalline cluster of HSV-
1 NCs. Note the very regular and dense array of exclusively empty
HSV-1 NCs.
Found at: doi:10.1371/journal.ppat.1001266.s004 (1.48 MB TIF)
Figure S5 Only PML IV promotes the redistribution of ORF23
protein in VZV infected cells. Representative confocal microscopy
images show the localization of EGFP-tagged PML-NBs (green)
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isoforms I, II, III, IV, V and VI (lower panels); the upper panels
show the localization of the isoforms expressing EGFP and the
ORF23 protein (red) in transfected cells that were infected with
VZV and examined at 48 hr post infection. Nuclei were stained
with Hoechst (blue). Only PML IV substantially redistributes
ORF23 protein as shown by colocalization in merged images
(white arrows).
Found at: doi:10.1371/journal.ppat.1001266.s005 (3.42 MB TIF)
Figure S6 Immobilization of ORF23 capsid protein by PML IV
nuclear bodies in living infected cells. Melanoma cells were
transfected with EGFP-PML IV (green) and infected for 48 hr
with rOka-RFP-ORF23; this virus expresses the ORF23 capsid
protein tagged with RFP. In the pre-bleach panels, live imaging
identified EGFP-PML IV bodies (green) that colocalized with
RFP-ORF23 protein (red). White arrowheads indicate RFP-
ORF23/EGFP-PML IV NBs. The RFP-fluorescence was then
selectively bleached (RFP-bleaching) with the 594 nm laser line
(bleached area in red); the white circle demarcates the area that
was excluded from bleaching and contained two PML IV NBs.
The post-bleach panels show imaging done at 15, 30 and 45 min
after RFP-bleaching to follow the fate of the bleached and
unbleached RFP-ORF23/EGFP-PMLIV complexes. Immobilized
ORF23 protein (red) remained confined to the area of PML-NBs
(green) up to 45 min after laser bleaching. Scale bar, 5 mm.
Found at: doi:10.1371/journal.ppat.1001266.s006 (1.03 MB TIF)
Figure S7 PML IV-NBs do not colocalize with VZV replication
compartments. Representative fluorescent microscopy images
show several EGFP-PML IV bodies (green) and VZV replication
compartments (red) that were visualized by staining with
antibodies to the ORF29 single stranded DNA binding protein
(A) or IE62 (B) or by detection of VZV genomic DNA using in situ
hybridization (C) at 48 hr post infection. Nuclei were stained with
Hoechst-stain (blue).
Found at: doi:10.1371/journal.ppat.1001266.s007 (1.87 MB TIF)
Figure S8 Characterization of doxycycline inducible cell lines
that express PML IV or PML IV-D 8AB.(A) Characterization of
doxycycline-inducible PML IV (left panel) and PML IV- D 8AB
(right panel) melanoma cell lines. Cells were uninduced (-) or
induced (+) with doxycycline (5 mg/ml) overnight, fixed and
stained for PML (green) and DNA (Hoechst stain, blue). (B)
Western blots of whole cell lysates from uninduced (left panel) and
induced cells (right panel) were probed with anti-PML polyclonal
rabbit antibody and tubulin specific antibody. (C) Annexin V
staining for the percentage of apoptotic cells at 24 hr after
induction of PML IV (left panel) and PML IV-D 8AB (right panel)
expressing cell lines. The arrow shows Annexin V-positive cells.
Quantification of approximately 5,500 cells of each cell line (11
microscopic fields with 500 cells each) showed no significant
difference in the percentage of apoptotic cells between cell lines
after induction (p=0.55).
Found at: doi:10.1371/journal.ppat.1001266.s008 (2.58 MB TIF)
Figure S9 Ultrastructure of PML IV cages with entrapped VZV
nucleocapsids. (A and B) Cells induced to express PML IV and
infected with VZV for 48 hr were high-pressure frozen, freeze
substituted and embedded in Epoxy resin. PML protein was
identified by specific immunogold labeling (PML-15 nm) (A)
Comparison of an infected nucleus without PML cages (left panel)
and an infected nucleus that contains a large PML cage (right
panel, arrow). (B) Comparison of the ultrastructure of PML cages
in sections not labeled for PML (left panel) with PML cages
identified by PML-specific immunogold labeling (15 nm particles,
right panel, arrowheads). PML cages are unequivocally identified
only by specific PML immunogold labeling (right panel). (C) Cells
induced to express PML IV and infected with VZV for 48 hr were
high-pressure frozen, freeze substituted and embedded in LR-
White resin for immuno-EM. PML protein was identified by
specific immunogold labeling (PML-15 nm). Arrows identify two
large PML cages shown at higher magnification in the right
panels. Note that the PML cages are densely labeled with PML
specific gold particles.
Found at: doi:10.1371/journal.ppat.1001266.s009 (3.71 MB TIF)
Table S1 Sequences of primers used for the construction of
PML deletion mutants.
Found at: doi:10.1371/journal.ppat.1001266.s010 (0.05 MB
DOC)
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